HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Icrucumab

for treatment of locally advanced or metastatic breast

Networked: 5 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Gao, Ling: 2 articles (01/2017 - 01/2016)
2.	Tang, Shande: 2 articles (01/2017 - 01/2016)
3.	Yin, Gang: 1 article (07/2022)
4.	Zhao, Ling: 1 article (07/2022)
5.	Dalal, Rita P: 1 article (01/2017)
6.	Garcia, Agustin A: 1 article (01/2017)
7.	Gradishar, William: 1 article (01/2017)
8.	Joy, Anil: 1 article (01/2017)
9.	Kauh, John: 1 article (01/2017)
10.	Khatcheressian, James: 1 article (01/2017)

Related Diseases

1.	Disease Progression 12/01/2016 - "This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan. " 12/01/2016 - "Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy."
2.	Colorectal Neoplasms (Colorectal Cancer) 12/01/2016 - "This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan. " 12/01/2016 - "Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy."
3.	Neoplasms (Cancer) 04/01/2014 - "Based on achievement of stable disease, icrucumab has potential for antitumor activity against advanced solid tumors." 04/01/2014 - "The primary objective was to determine the safety profile and maximum tolerated dose of icrucumab in patients with advanced solid tumors that were previously unresponsive to standard therapy or for which no standard therapy was available. " 04/01/2014 - "Overall, icrucumab exhibited nonlinear pharmacokinetics at doses >6 mg/kg. Six patients (23.1 %) achieved stable disease with median duration of 11.1 weeks (range = 10.3-18.7 weeks); tumor types were thyroid, melanoma, colorectal (3 patients), and small-cell lung cancers. " 04/01/2014 - "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study."
4.	Carcinoma (Carcinomatosis) 01/01/2016 - "Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial." 01/01/2016 - "This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after progression during or within 12 months of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma. "
5.	Breast Neoplasms (Breast Cancer) 01/01/2017 - "Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer."

Related Drugs and Biologics

1.	Ramucirumab
2.	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)
3.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
4.	Platinum
5.	Monoclonal Antibodies
6.	Irinotecan (Camptosar)
7.	Docetaxel (Taxotere)
8.	Capecitabine (Xeloda)

Related Therapies and Procedures

1.	Therapeutics